Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05686668
Other study ID # CHEsquirol
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date January 10, 2022
Est. completion date January 10, 2024

Study information

Verified date January 2024
Source Centre Hospitalier Esquirol
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The perception of the environment through the study of sensory awareness is important to understand the adaptive or symptomatological behaviors (e.g., withdrawal, increased activity level, stimulation seeking, etc.). Sensory processing disorders, such as hypersensitivities or hyposensitivities, have been described in people with depression using the Adolescent Adult Sensory Profile scale. In a recent study, similar results consistent with extreme sensory profiles (hypersensitivity, hyposensitivity, sensation avoidance) in adults with a major depressive disorder were observed. The evolution over time of the sensory profile in people with a depressive disorder is not known. It is currently unknown whether these extreme sensory processing profiles are stable over time or whether they may evolve with the depressive symptomatology to normalize with clinical improvement. This knowledge could have an important impact both on the symptomatological expression of the disorder, its recognition, and also on the management of the patient. The investigators aim to study the evolution over time of the sensory profile of depressed subjects hospitalized using the ASSP. The behavioral responses of individuals with sensory processing disorder may be related to the coping strategies of these individuals with their living environment. In a second step, the investigators will study the second step the sensory profile of subjects with depression according to their coping strategies, their living environment and their clinical characteristics (anxiety (anxiety, psychomotor slowing, self-esteem, anhedonia).


Description:

Main objective To compare the sensory profiles, i.e., the distribution of sensory processing patterns at each quadrant of the AASP, of subjects with major depressive disorder at the beginning of hospitalization (V1), and 3 months later (V2). Secondary objectives - Objective 1: To describe at V1 and V2, the sensory profiles according to the clinical characteristics (anxiety, depression, psychomotor slowing, self-esteem, anhedonia); a difference in the relationship between the clinical scales and the quadrants (AASP) at V2 and V1 could be observed. - Objective 2: To look for a difference in sensory profile at V2 according to clinical improvement - Objective 3: To compare, at V1, the distribution of processing patterns of sensory profiles for each quadrant of the AASP, according to coping styles (CISS). - Objective 4: To compare the distribution of processing patterns of sensory profiles sensory profiles for each quadrant of the AASP, according to socio-demographic characteristics: gender, age group, professional category, type of type of housing, environment, family situation - Objective 5: To look for a difference in the distribution of the processing patterns sensory profiles between the first inclusion visit (V1) and 3 months (V2), according to the type of drug treatment (molecules and classes) and non (psychotherapy, relaxation, rTMS, ECT) Inclusion criteria - Male or female, 18 to 65 years of age - who have given informed consent - with a diagnosis of a major depressive disorder according to the DSM-5 criteria - in full hospitalization for less than 10 days in the care units of the Esquirol Hospital Non inclusion criteria - Psychiatric comorbidity (personality disorder, addiction other than tobacco, eating disorder, bipolar disorder, obsessive-compulsive disorder, schizophrenia and related disorders) - Sensory or neurological disability - Inability to understand the questionnaires and information related to the study - Hospitalization under constraint, pregnancy, subjects under guardianship or curatorship, lack of social protection Outcome Measures Primary endpoints - AASP at V1 and V2 Secondary endpoints 1. AASP, HARS, HAM-D, CORE, EES-10, SHAPS at V1 and V2 2. AASP, HAM-D at V2 3. AASP, ISSC 4. AASP scores and socio-demographic characteristics (age, sex ratio, living environment, family status, housing) 5. AASP scores and treatments at V1 and V2


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 35
Est. completion date January 10, 2024
Est. primary completion date January 10, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Male or female, 18 to 65 years of age - who have given informed consent - with a diagnosis of a major depressive disorder according to the DSM-5 criteria - in full hospitalization for less than 10 days in the care units of the Esquirol Hospital Exclusion Criteria: - Psychiatric comorbidity (personality disorder, addiction other than tobacco, eating disorder, bipolar disorder, obsessive-compulsive disorder, schizophrenia and related disorders) - Proven sensory or neurological disability - Inability to understand the questionnaires and information related to the study - Hospitalization under constraint, pregnancy, subjects under guardianship or curatorship, lack of social protection

Study Design


Intervention

Other:
assessment by scales
Assessment from many scales: AASP, HARS, HDRS, CORE, EES, CISS, SHAPS at V1 Assessment from many scales: AASP, HARS, HDRS, CORE, EES, SHAPS at V2

Locations

Country Name City State
France CH Esquirol Limoges

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Esquirol

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Adolescent Adult Sensory Profile score measure a change in Adolescent Adult Sensory Profile score between he beginning of hospitalization and 3 months day 0 and 3 months
Secondary Hamilton Anxiety Rating Scale score measure a change in Adolescent Adult Sensory Profile score according to the HARS day 0 and 3 months
Secondary number of participants with psychomotor retardation measure a change in Adolescent Adult Sensory Profile score according to the psychomotor retardation-CORE scale day 0 and 3 months
Secondary Snaith-Hamilton pleasure scale score measure a change in Adolescent Adult Sensory Profile score according to SHAPS score day 0 and 3 months
Secondary Coping Inventory for Stressful Situations score the distribution of processing patterns of sensory profiles were compared according to coping styles based on CISS score day 0
Secondary number of participants living in country compare the Adolescent Adult Sensory Profile score according to living environment (country or town) day 0
Secondary number of participants living lonely compare the Adolescent Adult Sensory Profile score according to the family status (living alone or with people) day 0
Secondary Treatments measure a change in Adolescent Adult Sensory Profile score according to the traitments (antidepressant, anxiolytic, neuroleptic, psycho-corporal therapy) day 0 and 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4